GlassScriptPhysician profile
Sean Sliman
NPI 1861734014
$12,339.29
in general payments reported to CMS, 2019-2025
29 companies · $1,628 in 2025
The $1,628 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $148 · 2021: $270 · 2022: $1,481 · 2023: $3,818 · 2024: $4,685 · 2025: $1,628.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,085 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,800 · Travel and Lodging: $246.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,084.82 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,800.00 |
| Travel and Lodging | $246.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $5,236.09 | 2023-2024 | Indigo System |
| Pfizer INC. | $710.94 | 2022-2025 | |
| Abbott Laboratories | $635.30 | 2019-2025 | Xience Skypoint, Pressurewire, Diamondback Coronary |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $585.06 | 2020-2025 | Lifevest |
| Amgen INC. | $579.91 | 2021-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $578.23 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $509.60 | 2023-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $469.81 | 2021-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $428.47 | 2022-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $408.43 | 2021-2025 | Farxiga, Brilinta |
| Novo Nordisk INC | $382.15 | 2023-2025 | Wegovy, Ozempic |
| Cardiva Medical, INC. | $337.96 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs, Optowire |
| Abiomed | $229.75 | 2022-2025 | Impella |
| Inari Medical, INC. | $144.17 | 2021 | |
| Philips North America LLC | $139.41 | 2023-2025 | (Ck4) Mcot, Mcot, (Ck7) Extended Holter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $134.52 | 2019 | |
| Shockwave Medical, INC | $129.56 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Kiniksa Pharmaceuticals International, Plc | $106.19 | 2024 | Arcalyst |
| Chiesi USA, INC. | $96.85 | 2025 | Kengreal |
| Atricure, INC. | $96.09 | 2022-2023 | |
| Kestra Medical Technology Services, INC. | $89.89 | 2024-2025 | Assure Wcd |
| Actelion Pharmaceuticals US, INC. | $65.16 | 2022-2025 | Uptravi, Opsumit |
| Medtronic, INC. | $58.84 | 2021-2024 | Pulseselect, Linq II |
| Boston Scientific Corporation | $51.96 | 2019 | |
| Stryker Corporation | $49.24 | 2025 | Flowtriever |
| Kiniksa Pharmaceuticals, LTD. | $35.88 | 2023 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $21.63 | 2024 | |
| Biotronik INC. | $16.30 | 2023 | Orsiro Mission, Trapit, Nhancer Rx |
| Cardiovascular Systems INC. | $11.90 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sean Sliman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.